Meta analysis of Xuesaitong injection in the treatment of angina pectoris of coronary heart disease

摘要

Objective:To evaluate the efficacy and safety of Xuesaitong Injection in the treatment of angina pectoris.Methods:CNKI and WAN were retrieved Fang,VIP,CBMdisc,PubMed and Cochrane libraries published a randomized controlled trial of Xuesaitong Injection in the treatment of angina pectoris of coronary heart disease from the beginning of the establishment of the database to January 2020.29 cases were finally included in the study through layer by layer selection.The total sample size was 2560 cases,including 1307 cases in the experimental group and 1253 cases in the control group.The data collected were meta analyzed by Revman 5.3 software.Results:on the basis of routine western medicine treatment,Xuesaitong injection was added in the clinical comprehensive effective rate([RR=1.31;95%CI(1.25,1.39)]),angina symptom improvement rate([RR=1.16;95%CI(1.07,1.26)]),ECG improvement rate([RR=1.25;95%CI(1.14,1.38)]),angina attack times([RR=-2.49;95%CI(-3.27,-1.70)]);fibrinogen([MD=-0.61;95%CI(-0.77,-0.45)]),plasma(specific)viscosity([MD=-0.19;95%CI(-0.22,-0.16)]),hematocrit([MD=-0.04;95%CI(-0.05,-0.03)])and other aspects were superior to the conventional treatment of Western medicine,the difference was statistically significant.Safety aspect:the reported adverse reactions were mild and tolerable events such as headache,dizziness,flush,etc.,no serious adverse events,and no separation from the report was found.Conclusion:on the basis of conventional western medicine,Xuesaitong injection can effectively improve the clinical efficacy,and has a high safety.However,due to the low quality of the included study and the small sample size,there is a potential bias in the study;therefore,the application and promotion of the research conclusions need to be cautious,and need to be further verified by more large sample,multicenter,double-blind clinical randomized controlled trials.